A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems

A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems

Adjusting dosing regimens based on measurements of carbapenem levels may improve carbapenem exposure in patients. This systematic review aims to describe the effect carbapenem therapeutic drug monitoring (TDM) has on health outcomes, including the emergence of antimicrobial resistance (AMR). Four da...

Full description

Bibliographic Details
Main Authors:	Timothy N. Luxton, Natalie King, Christoph Wälti, Lars J. C. Jeuken, Jonathan A. T. Sandoe
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Antibiotics
Subjects:	carbapenem beta-lactam meropenem therapeutic drug monitoring clinical outcomes antimicrobial resistance
Online Access:	https://www.mdpi.com/2079-6382/11/10/1311

Similar Items

Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy
by: Nosheen Nasir, et al.
Published: (2019-09-01)

Carbapenems in clinical practice
by: S.O. Kramarov, et al.
Published: (2019-03-01)

Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
by: Fred C. Tenover, et al.
Published: (2006-08-01)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
by: Xi You, et al.
Published: (2024-03-01)

Mechanisms of Action of Carbapenem Resistance
by: Caterina Aurilio, et al.
Published: (2022-03-01)

24/7 Therapeutic Drug Monitoring of Beta-Lactam Antibiotics with CLAM-2000
by: Tatjana Khromov, et al.
Published: (2023-10-01)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
by: Tanaya Bhowmick, et al.
Published: (2020-10-01)

Carbapenems as Antidotes for the Management of Acute Valproic Acid Poisoning
by: Nataša Perković Vukčević, et al.
Published: (2024-02-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
by: I. I. Shteynberg, et al.
Published: (2015-03-01)

Meropenem allergy testing performed at the bedside of hospitalized patients labelled with a penicillin allergy
by: Laura Marín, et al.
Published: (2023-10-01)

Are the Newer Carbapenems of Any Value against Tuberculosis
by: Ximena Gonzalo, et al.
Published: (2022-08-01)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01)

Beta-Lactams Therapeutic Monitoring in Septic Children–What Target Are We Aiming for? A Scoping Review
by: Ronaldo Morales Junior, et al.
Published: (2022-03-01)

Etymologia: Carbapenem
by: Ronnie Henry
Published: (2019-07-01)

Exogenous glutathione reverses meropenem resistance in carbapenem-resistant Klebsiella pneumoniae
by: Juan Yi, et al.
Published: (2023-12-01)

Carbapenem resistance associated with coliuria among outpatient and hospitalised urology patients
by: A.A. Adegoke, et al.
Published: (2022-07-01)

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
by: Nicholas Rebold, et al.
Published: (2023-02-01)

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate
by: Yue-E Wu, et al.
Published: (2020-09-01)

Management of Beta-Lactam Antibiotics Allergy: A Real-Life Study
by: Sarah Iuliano, et al.
Published: (2022-04-01)

Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Enterobacter cloacae</italic>
by: Tae Hwan Kim, et al.
Published: (2020-02-01)

Prevalence of Carbapenem Resistance in Acinetobacter baumannii Isolates from Burn and Non-Burn Patients in Tehran
by: Zahra Ghareboghy Sarmad, et al.
Published: (2015-09-01)

Prevalence of Carbapenem Resistance in Acinetobacter baumannii Isolates from Burn and Non Burn Patients in Tehran
by: Zahra Ghareboghy-Sarmad, et al.
Published: (2015-11-01)

Overview and Insights into Carbapenem Allergy
by: Yuman Lee, et al.
Published: (2019-08-01)

Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis
by: Sharon Lechtig-Wasserman, et al.
Published: (2021-02-01)

Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study
by: Tim M. J. Ewoldt, et al.
Published: (2022-07-01)

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit
by: Carlos R.V. Kiffer, et al.

Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis
by: Pengxiang Zhou, et al.
Published: (2021-09-01)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021-03-01)

LC–MS/MS method for simultaneous quantification of ten antibiotics in human plasma for routine therapeutic drug monitoring
by: Mirjana Radovanovic, et al.
Published: (2022-11-01)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
by: Sergey Zyryanov, et al.
Published: (2023-03-01)

Metallo-β-lactamase-production in meropenem-susceptible Pseudomonas aeruginosa isolates: risk for silent spread
by: Renata Cristina Picão, et al.
Published: (2012-09-01)

Evaluation of a Computerized Decision Support Intervention to Decrease Use of Anti-Pseudomonal Carbapenems in Penicillin Allergic Patients
by: Christina Caplinger, et al.
Published: (2016-01-01)

Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies
by: Eszter Gulyás, et al.
Published: (2024-04-01)

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
by: Richard eWatkins, et al.
Published: (2013-12-01)

Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review
by: Abdul Haseeb, et al.
Published: (2022-09-01)

Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016–2022
by: Jennifer Lee, et al.
Published: (2023-10-01)

In vitro activity of biapenem and other carbapenems against Russian clinical isolates of Pseudomonas aeruginosa, Acinetobacter spp., and Enterobacterales
by: Kozlov R.S., et al.
Published: (2021-09-01)

Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity
by: Amy Legg, et al.
Published: (2023-05-01)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
by: Emmanuel Novy, et al.
Published: (2023-03-01)

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory
by: Carmella Russo, et al.
Published: (2023-12-01)